ACR 2026: Novartis/Abogen’s mRNA T-Cell Engager Shows Initial Promise In Scleroderma
In an investigator-initiated trial in Chinese scleroderma patients, ABO2203 caused no cytokine release syndrome or immune effector cell-associated…
Browsing Tag